Catalyst Pharmaceuticals Inc

CPRX

Equity

ISIN US14888U1016 / Valor 2649177

NASDAQ (2024-09-18)

USD 20.43-0.05%

Catalyst Pharmaceuticals Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Catalyst Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company that specializes in the in-licensing, development, and commercialization of innovative treatments for patients with rare diseases. The company's primary focus is on addressing unmet medical needs by bringing novel therapeutic options to market. Catalyst Pharmaceuticals leverages its expertise in drug development and regulatory processes to advance its pipeline of products, aiming to improve the quality of life for individuals affected by rare and debilitating conditions.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

In the first quarter of 2024, Catalyst Pharmaceuticals Inc. reported a significant increase in total revenues, reaching $98.5 million. This represents a 15.4% growth compared to the $85.4 million recorded in the first quarter of 2023. This increase is attributed to sustained demand for the company's commercial products.

FIRDAPSE Performance

For Q1 2024, Catalyst Pharmaceuticals Inc. saw robust growth in net product revenues from FIRDAPSE, which amounted to $66.8 million. This figure marks a 16.2% increase from the $57.5 million reported in the same quarter the previous year, highlighting strong market performance and continued product demand.

AGAMREE Launch Success

Catalyst Pharmaceuticals Inc. successfully launched AGAMREE in the U.S. on March 13, 2024. Despite being in the market for only two weeks in Q1 2024, AGAMREE generated net product revenues of $1.2 million. Early indicators suggest that the product uptake is exceeding initial expectations, showcasing a promising start.

Net Income and Earnings Per Share

The company reported a GAAP net income of $23.3 million in Q1 2024, with earnings per diluted share at $0.19. This represents a decrease from Q1 2023's net income of $29.6 million, or $0.26 per diluted share. Non-GAAP net income remained stable at $46.8 million, with non-GAAP earnings per diluted share at $0.38.

2024 Financial Outlook

Catalyst Pharmaceuticals Inc. reaffirmed its revenue guidance for the full year of 2024, projecting total revenues to be between $455 million and $475 million. This outlook reflects the company's confidence in continued revenue growth driven by its innovative product offerings and strong market execution.

Summarized from source with an LLMView Source

Key figures

61.9%1Y

305%3Y

212%5Y

Performance

45.5%1Y

54.8%3Y

59.9%5Y

Volatility